Literature DB >> 17909794

Imaging the norepinephrine transporter with positron emission tomography: initial human studies with (S,S)-[18F]FMeNER-D2.

Akihiro Takano1, Balázs Gulyás, Andrea Varrone, Per Karlsson, Magnus Schou, Anu J Airaksinen, Francois Vandenhende, Johannes Tauscher, Christer Halldin.   

Abstract

INTRODUCTION: (S,S)-[(18)F]FMeNER-D(2) is a recently developed positron emission tomography (PET) ligand for in vivo quantification of norepinephrine transporter. A monkey occupancy study with the radioligand indicated that (S,S)-[(18)F]FMeNER-D(2) can be useful for quantitative PET analysis. In this preliminary study, regional distributions in the living human brain were evaluated.
MATERIALS AND METHODS: Brain PET measurements were performed for a total of 255 min after the injection of 188.3 +/- 5.7 MBq of (S,S)-[(18)F]FMeNER-D(2) in four healthy male subjects. Regions of interests were drawn on the thalamus and the caudate in the coregistered MRI/PET images.
RESULTS: (S,S)-[(18)F]FMeNER-D(2) displayed good brain penetration and selective retention in regions rich in norepinephrine reuptake sites. The transient peak equilibrium was reached during the PET measurements. The ratios of radioactivity uptake in the thalamus to that in the caudate were 1.50 +/- 0.06 for the time period of 90-255 min.
CONCLUSION: The present preliminary investigation indicates that (S,S)-[(18)F]FMeNER-D(2) has suitable characteristics for probing the norepinephrine reuptake system with PET in the human brain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909794     DOI: 10.1007/s00259-007-0598-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  10 in total

1.  Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Authors:  Nicholas Seneca; Balázs Gulyás; Andrea Varrone; Magnus Schou; Anu Airaksinen; Johannes Tauscher; Francois Vandenhende; William Kielbasa; Lars Farde; Robert B Innis; Christer Halldin
Journal:  Psychopharmacology (Berl)       Date:  2006-08-04       Impact factor: 4.530

2.  Specific in vitro binding of (S,S)-[3H]MeNER to norepinephrine transporters.

Authors:  Subroto Ghose; Masahiro Fujita; Paul Morrison; George Uhl; Dennis L Murphy; P David Mozley; Magnus Schou; Christer Halldin; Robert Innis
Journal:  Synapse       Date:  2005-05       Impact factor: 2.562

3.  Whole-body biodistribution, radiation dosimetry estimates for the PET norepinephrine transporter probe (S,S)-[18F]FMeNER-D2 in non-human primates.

Authors:  Nicholas Seneca; Bengt Andree; Nils Sjoholm; Magnus Schou; Stefan Pauli; P David Mozley; James B Stubbs; Jeih-San Liow; Judit Sovago; Balazs Gulyás; Robert Innis; Christer Halldin
Journal:  Nucl Med Commun       Date:  2005-08       Impact factor: 1.690

4.  Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter.

Authors:  Alan A Wilson; David Patrick Johnson; David Mozley; Doug Hussey; Nathalie Ginovart; Jose Nobrega; Armando Garcia; Jeffery Meyer; Sylvain Houle
Journal:  Nucl Med Biol       Date:  2003-02       Impact factor: 2.408

5.  Post-mortem human brain autoradiography of the norepinephrine transporter using (S,S)-[18F]FMeNER-D2.

Authors:  Magnus Schou; Christer Halldin; Victor W Pike; P David Mozley; David Dobson; Robert B Innis; Lars Farde; Håkan Hall
Journal:  Eur Neuropsychopharmacol       Date:  2005-04-07       Impact factor: 4.600

Review 6.  Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder.

Authors:  J Biederman; T Spencer
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

7.  Specific in vivo binding to the norepinephrine transporter demonstrated with the PET radioligand, (S,S)-[11C]MeNER.

Authors:  Magnus Schou; Christer Halldin; Judit Sóvágó; Victor W Pike; Balázs Gulyás; P David Mozley; David P Johnson; Håkan Hall; Robert B Innis; Lars Farde
Journal:  Nucl Med Biol       Date:  2003-10       Impact factor: 2.408

8.  Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs.

Authors:  Yu-Shin Ding; Kuo-Shyan Lin; Victor Garza; Pauline Carter; David Alexoff; Jean Logan; Colleen Shea; Youwen Xu; Payton King
Journal:  Synapse       Date:  2003-12-15       Impact factor: 2.562

9.  Norepinephrine and its metabolites in cerebrospinal fluid, plasma, and urine. Relationship to hypothalamic-pituitary-adrenal axis function in depression.

Authors:  A Roy; D Pickar; J De Jong; F Karoum; M Linnoila
Journal:  Arch Gen Psychiatry       Date:  1988-09

10.  PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain.

Authors:  Magnus Schou; Christer Halldin; Judit Sóvágó; Victor W Pike; Håkan Hall; Balázs Gulyás; P David Mozley; David Dobson; E Shchukin; Robert B Innis; Lars Farde
Journal:  Synapse       Date:  2004-08       Impact factor: 2.562

  10 in total
  9 in total

1.  Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study.

Authors:  Akihiro Takano; Christer Halldin; Andrea Varrone; Per Karlsson; Nils Sjöholm; James B Stubbs; Magnus Schou; Anu J Airaksinen; Johannes Tauscher; Balázs Gulyás
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11-14       Impact factor: 9.236

2.  Is this Red Spot the Blue Spot (locus ceruleus)?

Authors:  Wonsick Choe; Yukyung Lee; Minkyung Lee; Kyung Hoon Hwang
Journal:  Nucl Med Mol Imaging       Date:  2010-04-21

3.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

4.  Norepinephrine transporter occupancy by antidepressant in human brain using positron emission tomography with (S,S)-[18F]FMeNER-D2.

Authors:  Mizuho Sekine; Ryosuke Arakawa; Hiroshi Ito; Masaki Okumura; Takeshi Sasaki; Hidehiko Takahashi; Harumasa Takano; Yoshiro Okubo; Christer Halldin; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2010-03-23       Impact factor: 4.530

5.  Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging of the norepinephrine transporter.

Authors:  Fanxing Zeng; Jiyoung Mun; Nachwa Jarkas; Jeffrey S Stehouwer; Ronald J Voll; Gilles D Tamagnan; Leonard Howell; John R Votaw; Clinton D Kilts; Charles B Nemeroff; Mark M Goodman
Journal:  J Med Chem       Date:  2009-01-08       Impact factor: 7.446

6.  Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2).

Authors:  Akihiro Takano; Balázs Gulyás; Andrea Varrone; Ralph Paul Maguire; Christer Halldin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-20       Impact factor: 9.236

7.  The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography.

Authors:  Thomas Vanicek; Marie Spies; Christina Rami-Mark; Markus Savli; Anna Höflich; Georg S Kranz; Andreas Hahn; Alexandra Kutzelnigg; Tatjana Traub-Weidinger; Markus Mitterhauser; Wolfgang Wadsak; Marcus Hacker; Nora D Volkow; Siegfried Kasper; Rupert Lanzenberger
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

8.  Central nervous system drug evaluation using positron emission tomography.

Authors:  Mizuho Sekine; Jun Maeda; Hitoshi Shimada; Tsuyoshi Nogami; Ryosuke Arakawa; Harumasa Takano; Makoto Higuchi; Hiroshi Ito; Yoshiro Okubo; Tetsuya Suhara
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-04-30       Impact factor: 2.582

9.  Decreased defluorination using the novel beta-cell imaging agent [18F]FE-DTBZ-d4 in pigs examined by PET.

Authors:  Mahabuba Jahan; Olof Eriksson; Peter Johnström; Olle Korsgren; Anders Sundin; Lars Johansson; Christer Halldin
Journal:  EJNMMI Res       Date:  2011-12-05       Impact factor: 3.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.